Arnar Astradsson1, Tipu Z Aziz. 1. Department of Neurorehabilitation, Traumatic Brain Injury Unit, Copenhagen University Hospital of Glostrup, Copenhagen, Denmark.
Abstract
INTRODUCTION: The mean age of onset of Parkinson's disease is about 65 years, with a median time of 9 years between diagnosis and death. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of fetal cell or stem cell-derived therapy in people with Parkinson's disease? We searched: Medline, Embase, The Cochrane Library and other important databases up to September 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found two studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: fetal cell therapy versus deep brain stimulation; fetal cell therapy versus sham surgery; stem cell-derived therapy versus deep brain stimulation; stem cell-derived therapy versus sham surgery.
INTRODUCTION: The mean age of onset of Parkinson's disease is about 65 years, with a median time of 9 years between diagnosis and death. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of fetal cell or stem cell-derived therapy in people with Parkinson's disease? We searched: Medline, Embase, The Cochrane Library and other important databases up to September 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found two studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: fetal cell therapy versus deep brain stimulation; fetal cell therapy versus sham surgery; stem cell-derived therapy versus deep brain stimulation; stem cell-derived therapy versus sham surgery.
Authors: Irene Litvan; Kailash P Bhatia; David J Burn; Christopher G Goetz; Anthony E Lang; Ian McKeith; Niall Quinn; Kapil D Sethi; Cliff Shults; Gregor K Wenning Journal: Mov Disord Date: 2003-05 Impact factor: 10.338
Authors: W K Scott; M A Nance; R L Watts; J P Hubble; W C Koller; K Lyons; R Pahwa; M B Stern; A Colcher; B C Hiner; J Jankovic; W G Ondo; F H Allen; C G Goetz; G W Small; D Masterman; F Mastaglia; N G Laing; J M Stajich; B Slotterbeck; M W Booze; R C Ribble; E Rampersaud; S G West; R A Gibson; L T Middleton; A D Roses; J L Haines; B L Scott; J M Vance; M A Pericak-Vance Journal: JAMA Date: 2001-11-14 Impact factor: 56.272
Authors: L Morgante; G Salemi; F Meneghini; A E Di Rosa; A Epifanio; F Grigoletto; P Ragonese; F Patti; A Reggio; R Di Perri; G Savettieri Journal: Arch Neurol Date: 2000-04
Authors: Yilong Ma; Chengke Tang; Thomas Chaly; Paul Greene; Robert Breeze; Stanley Fahn; Curt Freed; Vijay Dhawan; David Eidelberg Journal: J Nucl Med Date: 2009-12-15 Impact factor: 10.057
Authors: Cynthia McRae; Eva Cherin; T Gayle Yamazaki; Gretchen Diem; Alexander H Vo; Dan Russell; J Heiner Ellgring; Stanley Fahn; Paul Greene; Sandra Dillon; Hal Winfield; Kimberly B Bjugstad; Curt R Freed Journal: Arch Gen Psychiatry Date: 2004-04
Authors: C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman Journal: Ann Neurol Date: 2003-09 Impact factor: 10.422